US FDA allows Synta to resume development of anticancer elesclomol
03 March 2010
Malini Guha
Please Login to read the full article.
03 March 2010
Malini Guha
Malini.guha@informa.com
Synta Pharmaceuticals has received the go-ahead from the US FDA to resume development of its novel anticancer elesclomol, an oxidative stress inducer whose closely watched Phase III trial in metastatic melanoma was suspended last year on safety concerns.
"The collected clinical and preclinical...
Please Login to read the full article.
RELATED CONTENT
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
